tiprankstipranks
Trending News
More News >
Medartis Holding AG (CH:MED)
:MED
Switzerland Market
Advertisement

Medartis Holding AG (MED) AI Stock Analysis

Compare
1 Followers

Top Page

CH:MED

Medartis Holding AG

(MED)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 4o)
Rating:61Neutral
Price Target:
CHF87.00
▲(2.84% Upside)
Medartis Holding AG's overall score is driven by strong financial performance and positive technical trends. However, the valuation is significantly impacted by a negative P/E ratio and lack of dividend yield, which weigh down the overall attractiveness of the stock.
Positive Factors
Revenue Growth
Consistent revenue growth indicates robust demand for Medartis' products and effective market penetration, supporting long-term business expansion.
Cash Flow Improvement
Significant improvement in free cash flow enhances Medartis' ability to invest in growth opportunities and maintain financial flexibility.
Balance Sheet Health
A strong balance sheet with low leverage ensures Medartis can withstand economic downturns and invest in strategic initiatives.
Negative Factors
Low Net Profit Margin
Low net profit margins suggest challenges in cost management, potentially impacting profitability and limiting reinvestment capacity.
Modest Return on Equity
A modest ROE indicates inefficiencies in generating returns from equity, which could affect investor confidence and future capital raising.
Operational Efficiency
Moderate operational margins highlight the need for improved efficiency to enhance profitability and competitive positioning.

Medartis Holding AG (MED) vs. iShares MSCI Switzerland ETF (EWL)

Medartis Holding AG Business Overview & Revenue Model

Company DescriptionMedartis Holding AG (MED) is a leading Swiss company specializing in the development, manufacturing, and sale of innovative medical devices, specifically for the fields of osteosynthesis. The company's primary focus is on providing high-quality implants and instruments for the surgical fixation of bone fractures and osteotomies. Medartis operates primarily within the healthcare and medical technology sectors, striving to enhance surgical outcomes and patient recovery through its advanced product offerings.
How the Company Makes MoneyMedartis Holding AG generates revenue through the sale of its specialized medical devices and related instruments. The company markets a comprehensive portfolio of implants and surgical tools designed for cranial, upper, and lower extremity applications. Revenue streams are primarily derived from direct sales to hospitals, clinics, and healthcare providers, as well as through partnerships and distribution agreements with other medical technology companies and distributors globally. Medartis leverages its strong brand reputation, innovative product offerings, and extensive distribution network to maintain a steady stream of income. Additionally, the company invests in research and development to continuously improve its product line, which helps in sustaining competitive advantage and driving sales growth.

Medartis Holding AG Financial Statement Overview

Summary
Medartis Holding AG shows strong revenue growth and financial stability with a robust gross profit margin and improved cash flow. However, low net profit margins and modest return on equity indicate room for operational improvements.
Income Statement
75
Positive
Medartis Holding AG demonstrates a strong revenue growth trajectory with a 6% increase from 2023 to 2024. The gross profit margin has remained robust at approximately 79.5% in 2024. However, the net profit margin remains relatively low at 1.57%, indicating potential challenges in cost management or operational efficiency. The EBIT and EBITDA margins are moderate at 3.5% and 13.4% respectively, showing room for improvement in operational leverage.
Balance Sheet
82
Very Positive
The company maintains a healthy balance sheet with a favorable equity ratio of 58.6% in 2024, indicating a strong capital structure. The debt-to-equity ratio is at a manageable 0.45, reflecting prudent financial leverage. Return on equity is modest at 1.31%, suggesting potential underutilization of shareholder funds. Overall, the financial position is stable with potential for enhanced returns.
Cash Flow
78
Positive
Medartis Holding AG exhibits a significant improvement in free cash flow, growing from CHF 1.17 million in 2023 to CHF 21 million in 2024. The operating cash flow to net income ratio is strong, highlighting efficient cash conversion from profits. The free cash flow to net income ratio is robust at 5.95, underscoring efficient capital management. However, consistent positive cash flow generation remains critical for sustained financial health.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue224.83M212.01M182.82M159.88M127.65M
Gross Profit178.68M167.57M135.39M121.57M93.89M
EBITDA30.18M24.69M16.24M26.10M13.96M
Net Income3.53M619.00K-5.78M6.84M-943.57K
Balance Sheet
Total Assets459.96M349.53M327.89M298.18M282.79M
Cash, Cash Equivalents and Short-Term Investments138.69M25.20M20.60M82.64M82.73M
Total Debt120.29M26.92M52.04M24.07M27.18M
Total Liabilities190.31M94.58M90.11M74.18M69.76M
Stockholders Equity269.65M254.96M237.78M224.00M213.04M
Cash Flow
Free Cash Flow21.00M1.17M-22.72M10.57M-455.29K
Operating Cash Flow28.17M19.96M-3.93M20.95M12.61M
Investing Cash Flow-19.06M-37.83M-52.91M-15.87M-22.86M
Financing Cash Flow104.48M23.21M-3.90M-4.78M-4.73M

Medartis Holding AG Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price84.60
Price Trends
50DMA
86.18
Negative
100DMA
81.43
Positive
200DMA
74.87
Positive
Market Momentum
MACD
0.79
Positive
RSI
37.43
Neutral
STOCH
6.28
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MED, the sentiment is Neutral. The current price of 84.6 is below the 20-day moving average (MA) of 90.99, below the 50-day MA of 86.18, and above the 200-day MA of 74.87, indicating a neutral trend. The MACD of 0.79 indicates Positive momentum. The RSI at 37.43 is Neutral, neither overbought nor oversold. The STOCH value of 6.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:MED.

Medartis Holding AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
13.28B25.4520.28%1.99%6.58%-10.02%
73
Outperform
3.03B33.7619.20%0.47%16.59%65.76%
70
Outperform
3.62B22.7816.33%0.49%0.77%16.70%
68
Neutral
563.35M7.7095.80%58.51%
67
Neutral
1.98B31.214.71%2.01%-9.34%-37.50%
61
Neutral
CHF1.21B282.787.29%-112.70%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:MED
Medartis Holding AG
84.60
26.70
46.11%
CH:SOON
Sonova Holding AG
221.40
-77.21
-25.86%
CH:BSLN
Basilea Pharmaceutica
46.05
-0.30
-0.65%
MEDGF
Medacta Group SA
183.70
36.04
24.41%
SGFEF
Siegfried Holding AG
114.35
11.58
11.27%
TCHBF
Tecan Group AG
188.38
-136.42
-42.00%

Medartis Holding AG Corporate Events

Medartis to Present 2025 Half-Year Results via Webcast
Jul 30, 2025

Medartis Holding AG has announced a webcast presentation of its half-year results for 2025, scheduled for August 19, 2025. The event will feature presentations by CEO Matthias Schupp and CFO Dirk Kirsten, and will be available for viewing via MS Teams. This announcement signifies Medartis’s commitment to transparency and engagement with stakeholders, providing insights into its financial performance and strategic direction.

The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.

Medartis Completes Acquisition of KeriMedical to Bolster Hand Surgery Portfolio
Jul 17, 2025

Medartis Holding AG has acquired the remaining 53% of shares in KeriMedical, a company specializing in hand and wrist surgery implants, for CHF 99 million. This acquisition, following the FDA approval of KeriMedical’s TOUCH thumb prosthesis, strengthens Medartis’ position in joint replacement and expands its network of surgeons, with an immediate positive impact on sales growth and EBITDA margin. KeriMedical will continue as an independent brand within Medartis, retaining its development and marketing teams, while co-founders Dougal Bendjaballah and Bernard Prandi remain on the board. The acquisition enhances Medartis’ competencies in hand and wrist surgery, aligning with its strategic goals and expanding its market reach, particularly in Europe, the US, and Australia.

The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025